Invesco Ltd. Has $187,000 Holdings in ADC Therapeutics SA $ADCT

Key Points

• Invesco Ltd. increased its ownership of ADC Therapeutics SA by 286.1% in Q1, acquiring an additional 98,335 shares to hold a total of 132,704 shares valued at approximately $187,000.
• ADC Therapeutics' share price is currently at $3.51 after a 0.8% decline, with a market cap of about $395.21 million and a price-to-earnings ratio of -2.24.
• Research analysts maintain a consensus rating of "Buy" for ADC Therapeutics, with a range of price targets, including a high of $10.00 and a recent downgrade to $5.00.

Invesco Ltd. raised its holdings in ADC Therapeutics SA (NYSE:ADCT - Free Report) by 286.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 132,704 shares of the company's stock after purchasing an additional 98,335 shares during the period. Invesco Ltd. owned 0.13% of ADC Therapeutics worth $187,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. ProShare Advisors LLC increased its stake in ADC Therapeutics by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 22,901 shares of the company's stock worth $46,000 after buying an additional 7,535 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of ADC Therapeutics by 21.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,520 shares of the company's stock worth $93,000 after acquiring an additional 8,246 shares during the period. Wells Fargo & Company MN raised its holdings in shares of ADC Therapeutics by 39.4% in the 4th quarter. Wells Fargo & Company MN now owns 41,832 shares of the company's stock worth $83,000 after purchasing an additional 11,834 shares in the last quarter. Barclays PLC raised its holdings in shares of ADC Therapeutics by 10.8% in the 4th quarter. Barclays PLC now owns 141,495 shares of the company's stock worth $282,000 after purchasing an additional 13,756 shares in the last quarter. Finally, Deutsche Bank AG raised its holdings in shares of ADC Therapeutics by 40.7% during the fourth quarter. Deutsche Bank AG now owns 56,062 shares of the company's stock valued at $112,000 after acquiring an additional 16,217 shares during the period. Hedge funds and other institutional investors own 41.10% of the company's stock.

ADC Therapeutics Stock Down 0.6%

ADC Therapeutics stock traded down $0.02 during midday trading on Friday, hitting $3.31. 310,947 shares of the stock were exchanged, compared to its average volume of 628,960. The company has a fifty day simple moving average of $3.09 and a two-hundred day simple moving average of $2.39. ADC Therapeutics SA has a 52 week low of $1.05 and a 52 week high of $3.97. The stock has a market capitalization of $372.37 million, a PE ratio of -2.11 and a beta of 2.00.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.14). The business had revenue of $18.84 million for the quarter, compared to analysts' expectations of $17.82 million. As a group, equities research analysts anticipate that ADC Therapeutics SA will post -1.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ADCT shares. Wall Street Zen lowered shares of ADC Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Royal Bank Of Canada raised shares of ADC Therapeutics from an "outperform" rating to a "moderate buy" rating and decreased their price objective for the stock from $8.00 to $5.00 in a report on Friday, June 20th. Finally, Guggenheim reissued a "buy" rating and issued a $10.00 price target on shares of ADC Therapeutics in a report on Wednesday, August 13th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, ADC Therapeutics presently has a consensus rating of "Buy" and an average price target of $7.75.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.